<DOC>
	<DOC>NCT00103714</DOC>
	<brief_summary>The objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of two dose levels of INS37217 (denufosol tetrasodium) Inhalation Solution in patients with cystic fibrosis (CF) lung disease.</brief_summary>
	<brief_title>Study of Denufosol Tetrasodium in Patients With Cystic Fibrosis Lung Disease</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<criteria>Have confirmed diagnosis of CF Have an FEV1 greater than or equal to 60% or less than or equal to 90% of predicted normal Have oxygen saturation greater than or equal to 90% on room air Be clinically stable with no evidence of acute upper or lower respiratory tract infection or current pulmonary exacerbation Be able to reproducibly perform spirometry maneuvers Have changed their physiotherapy technique or schedule within 7 days prior to screening Have clinically significant comorbidities Using prior and concurrent medications according to the protocol</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>lung disease</keyword>
</DOC>